The MAGIA2Market partners are glad to announce the publication of their Japanese MedTech market study!
The report gathers the key features to know to approach the Medical Technology market in Japan. For the four clusters partners this study is a crucial resource, as it builds the first information basis for their SMEs in order to better understand and, therefore, assess their opportunities in the Japanese market. Overview of the healthcare and reimbursement systems, regulatory requirements, market access, market segmentation are among the various topics covered.
About MAGIA2Market:
MAGIA2Market is a European project dedicated to support SME Internationalisation in MedTech sector on three global markets: China, Japan and USA. MAGIA2Market follows the first phase of the MAGIA project, which ended on 31 December, 2019. The project gathers four European leading MedTech clusters: bioPmed (coordinator, Piedmont), BioWin (Wallonia), Life Science Nord (Northern Germany) and Lyonbiopole (Auvergne-Rhône-Alpes). The goal of MAGIA2Market is to provide SMEs the opportunity to meet with potential partners in China, Japan and USA, laying the groundwork for potential cooperation, both in terms of business agreements but also co-development or research collaboration.
Published: June 2021
The EU-Japan Centre currently produces 5 newsletters :
Joint venture established in 1987 by the European Commission (DG GROW) and the Japanese Government (METI) for promoting all forms of industrial, trade and investment cooperation between the EU and Japan.
The EU-Japan Centre’s activities are subject to the allocation of a Grant Agreement by the European Commission for 2024-2026